Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7485MR)

This product GTTS-WQ7485MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7485MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7007MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ2795MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ1624MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ5476MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ10025MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ3484MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ1204MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ13724MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48-0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW